Table 1.
Demographic and Clinical Characteristics of Participants
| Characteristic | Participants (n = 121), No. (%) a |
|---|---|
| Age, y (range) | 37 (21–62) |
| Sex | |
| Male | 120 (99) |
| Female | 1 (1) |
| Race | |
| White | 77 (64) |
| Black | 13 (11) |
| >1 race | 5 (4) |
| American Indian/Alaska Native | 4 (3) |
| Asian | 3 (2) |
| Native Hawaiian or Other Pacific Islander | 2 (2) |
| Unavailable or declined | 17 (14) |
| Ethnicity | |
| Hispanic or Latino | 37 (31) |
| Not Hispanic or Latino | 74 (61) |
| Unavailable or declined | 10 (8) |
| Risk factors for severe disease | |
| Well controlled HIV (CD4>200 and VL<200) | 71 (59) |
| Poorly controlled HIV (CD4<200 or VL>200) | 10 (8) |
| Immunocompromise (non-HIV) | 3 (2) |
| Atopic dermatitis | 1 (1) |
| Other exfoliative skin conditions | 5 (4) |
| Lesions in areas that might constitute a special hazard | |
| Anal/rectal/genital alone | 74 (61) |
| Oral alone | 10 (8) |
| Ocular alone | 1 (1) |
| Oral and anal/rectal/genital | 11 (9) |
| Ocular and anal/rectal/genital | 1 (1) |
| Prescribed tecovirimat | 112 (93) |
| Required hospitalization | 6 (5) |
Note. HIV, human immunodeficiency virus; CD4, T-lymphocyte; VL, viral load.
a
Units unless otherwise indicated.